BIOVENTUS INC - A (BVS) Stock Fundamental Analysis
NASDAQ:BVS - Nasdaq - US09075A1088 - Common Stock - Currency: USD
BVS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. While BVS is still in line with the averages on profitability rating, there are concerns on its financial health. BVS scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year BVS was profitable.
In the past year BVS had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BVS reported negative net income in multiple years.
BVS had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
BVS has a better Return On Assets (-4.61%) than 65.61% of its industry peers.
Looking at the Return On Equity, with a value of -22.67%, BVS is in the better half of the industry, outperforming 60.85% of the companies in the same industry.
BVS has a better Return On Invested Capital (3.76%) than 74.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.61% | ||
| ROE | -22.67% | ||
| ROIC | 3.76% |
ROA(3y)-11.81%
ROA(5y)-6.59%
ROE(3y)-54.27%
ROE(5y)-31.1%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BVS's Operating Margin of 4.29% is fine compared to the rest of the industry. BVS outperforms 70.90% of its industry peers.
BVS's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 67.72%, BVS is doing good in the industry, outperforming 74.60% of the companies in the same industry.
BVS's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.29% | ||
| PM (TTM) | N/A | ||
| GM | 67.72% |
OM growth 3Y-2.88%
OM growth 5Y-14.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.21%
GM growth 5Y-1.56%
2. Health
2.1 Basic Checks
BVS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, BVS has more shares outstanding
Compared to 5 years ago, BVS has more shares outstanding
BVS has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.88, we must say that BVS is in the distress zone and has some risk of bankruptcy.
BVS has a Altman-Z score of 0.88. This is comparable to the rest of the industry: BVS outperforms 49.74% of its industry peers.
The Debt to FCF ratio of BVS is 9.16, which is on the high side as it means it would take BVS, 9.16 years of fcf income to pay off all of its debts.
BVS's Debt to FCF ratio of 9.16 is fine compared to the rest of the industry. BVS outperforms 75.13% of its industry peers.
BVS has a Debt/Equity ratio of 2.15. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.15, BVS is not doing good in the industry: 83.60% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.15 | ||
| Debt/FCF | 9.16 | ||
| Altman-Z | 0.88 |
ROIC/WACC0.43
WACC8.71%
2.3 Liquidity
BVS has a Current Ratio of 1.31. This is a normal value and indicates that BVS is financially healthy and should not expect problems in meeting its short term obligations.
BVS's Current ratio of 1.31 is on the low side compared to the rest of the industry. BVS is outperformed by 79.37% of its industry peers.
BVS has a Quick Ratio of 1.31. This is a bad value and indicates that BVS is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.87, BVS is not doing good in the industry: 82.54% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
BVS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.45%, which is quite impressive.
The earnings per share for BVS have been decreasing by -16.93% on average. This is quite bad
Looking at the last year, BVS shows a quite strong growth in Revenue. The Revenue has grown by 11.89% in the last year.
The Revenue has been growing by 11.01% on average over the past years. This is quite good.
EPS 1Y (TTM)45.45%
EPS 3Y-16.93%
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)11.89%
Revenue growth 3Y9.98%
Revenue growth 5Y11.01%
Sales Q2Q%-4.31%
3.2 Future
The Earnings Per Share is expected to grow by 19.79% on average over the next years. This is quite good.
Based on estimates for the next years, BVS will show a small growth in Revenue. The Revenue will grow by 3.48% on average per year.
EPS Next Y41.11%
EPS Next 2Y38.04%
EPS Next 3Y19.79%
EPS Next 5YN/A
Revenue Next Year0.05%
Revenue Next 2Y3.03%
Revenue Next 3Y3.48%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 13.60, the valuation of BVS can be described as correct.
Based on the Price/Earnings ratio, BVS is valued cheaper than 88.36% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.82. BVS is valued slightly cheaper when compared to this.
The Price/Forward Earnings ratio is 7.29, which indicates a rather cheap valuation of BVS.
Based on the Price/Forward Earnings ratio, BVS is valued cheaper than 97.35% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.76. BVS is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.6 | ||
| Fwd PE | 7.29 |
4.2 Price Multiples
87.30% of the companies in the same industry are more expensive than BVS, based on the Enterprise Value to EBITDA ratio.
BVS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BVS is cheaper than 91.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.17 | ||
| EV/EBITDA | 11.3 |
4.3 Compensation for Growth
BVS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BVS's earnings are expected to grow with 19.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.33
PEG (5Y)N/A
EPS Next 2Y38.04%
EPS Next 3Y19.79%
5. Dividend
5.1 Amount
BVS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
6.53
+0.02 (+0.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners70.7%
Inst Owner Change5.28%
Ins Owners2.11%
Ins Owner Change2.24%
Market Cap535.59M
Analysts77.14
Price Target15.3 (134.3%)
Short Float %1.66%
Short Ratio2.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)88.12%
Min EPS beat(2)78.22%
Max EPS beat(2)98.02%
EPS beat(4)4
Avg EPS beat(4)137.71%
Min EPS beat(4)78.22%
Max EPS beat(4)192.41%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.03%
Min Revenue beat(2)3.27%
Max Revenue beat(2)4.79%
Revenue beat(4)4
Avg Revenue beat(4)6.29%
Min Revenue beat(4)3.27%
Max Revenue beat(4)8.81%
Revenue beat(8)8
Avg Revenue beat(8)4.99%
Revenue beat(12)9
Avg Revenue beat(12)1.91%
Revenue beat(16)12
Avg Revenue beat(16)2.56%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-61.12%
EPS NY rev (1m)0%
EPS NY rev (3m)19.39%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.81%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)1.91%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.6 | ||
| Fwd PE | 7.29 | ||
| P/S | 0.93 | ||
| P/FCF | 14.17 | ||
| P/OCF | 13.81 | ||
| P/B | 3.62 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.3 |
EPS(TTM)0.48
EY7.35%
EPS(NY)0.9
Fwd EY13.71%
FCF(TTM)0.46
FCFY7.06%
OCF(TTM)0.47
OCFY7.24%
SpS6.99
BVpS1.8
TBVpS-3.22
PEG (NY)0.33
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.61% | ||
| ROE | -22.67% | ||
| ROCE | 4.76% | ||
| ROIC | 3.76% | ||
| ROICexc | 4.09% | ||
| ROICexgc | 30.49% | ||
| OM | 4.29% | ||
| PM (TTM) | N/A | ||
| GM | 67.72% | ||
| FCFM | 6.59% |
ROA(3y)-11.81%
ROA(5y)-6.59%
ROE(3y)-54.27%
ROE(5y)-31.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y44.62%
ROICexcg growth 5Y-8.7%
ROICexc growth 3Y36.86%
ROICexc growth 5Y-12.41%
OM growth 3Y-2.88%
OM growth 5Y-14.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.21%
GM growth 5Y-1.56%
F-Score6
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.15 | ||
| Debt/FCF | 9.16 | ||
| Debt/EBITDA | 4.29 | ||
| Cap/Depr | 2.03% | ||
| Cap/Sales | 0.18% | ||
| Interest Coverage | 0.64 | ||
| Cash Conversion | 52.3% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 0.88 |
F-Score6
WACC8.71%
ROIC/WACC0.43
Cap/Depr(3y)9.96%
Cap/Depr(5y)13.06%
Cap/Sales(3y)1.19%
Cap/Sales(5y)1.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.45%
EPS 3Y-16.93%
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y41.11%
EPS Next 2Y38.04%
EPS Next 3Y19.79%
EPS Next 5YN/A
Revenue 1Y (TTM)11.89%
Revenue growth 3Y9.98%
Revenue growth 5Y11.01%
Sales Q2Q%-4.31%
Revenue Next Year0.05%
Revenue Next 2Y3.03%
Revenue Next 3Y3.48%
Revenue Next 5YN/A
EBIT growth 1Y1808.37%
EBIT growth 3Y6.82%
EBIT growth 5Y-5.11%
EBIT Next Year19.54%
EBIT Next 3Y13.24%
EBIT Next 5YN/A
FCF growth 1Y373.43%
FCF growth 3Y34.24%
FCF growth 5Y-0.3%
OCF growth 1Y152.84%
OCF growth 3Y19.05%
OCF growth 5Y-0.96%